NDAINJECTIONINJECTABLE
Approved
Jan 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
FUROSEMIDE (furosemide) by Medica Corp is clinical pharmacology investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. First approved in 1979.
Drug data last refreshed 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Furosemide is a potent loop diuretic approved in 1979 for treating heart failure, hypertension, renal impairment, and liver cirrhosis. It works by inhibiting sodium and chloride reabsorption in the proximal tubule, distal tubule, and loop of Henle, with onset of action within 5 minutes of IV administration. The drug is extensively plasma-protein bound (91-99%) and has a terminal half-life of approximately 2 hours.
LOE Approaching
Furosemide is approaching loss of exclusivity as a mature, generic-dominant product with limited commercial expansion potential and likely reduced headcount on the brand team.
Mechanism of Action
CLINICAL PHARMACOLOGY Investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that furosemide inhibits primarily the reabsorption…
Worked on FUROSEMIDE at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.